Because of the GKV law: Boehringer Ingelheim and Eli Lilly stop investing millions in Germany

The Palatinate family business does not want to spend almost a billion euros in Germany as planned. The reason is the government's planned health insurance reform. US rival Eli Lilly is even halving its billion-dollar investment in Germany.